Novo Nordisk Balances a $25M Ransom Demand and a High-Stakes FDA Decision as Shares Rebound
Novo Nordisk has clawed back more than a third of its value from March lows, yet the Danish…
Novo Nordisk Balances Amazon Access and Generic Onslaught as Pipeline Decision Looms
Novo Nordisk’s stock is squeezed between a landmark Amazon Pharmacy distribution deal and pricing erosion from Indian generics…
Novo Nordisk Balances Canadian Price Pressure With Sickle Cell Advance and Oral Pill Triumph
Novo Nordisk rebounds 31% on obesity data, but Canada generic semaglutide threatens pricing. Wegovy oral pill sales surge…